Avicena® to Present at BIO CEO & Investor Conference 2007

Results Pave Way for Phase III Study in Parkinson's Disease

Palo Alto, CA, February 12, 2007 — Avicena® Group, Inc. (OTCBB: AVGO), a late stage biotechnology company focused on commercializing its proprietary cellular energy modulation technology, announced today that chief executive officer Dr. Belinda Tsao-Nivaggioli will present a corporate overview on Wednesday, February 14, 2007, at 3:00 P.M. ET during the BIO CEO & Investor Conference - Investing in Biotechnology: The Value, the Risks, the Rewards, at the Waldorf-Astoria Hotel in New York City.

To access a live webcast of Dr. Tsao-Nivaggioli's presentation, please go to Avicena Group's website at www.avicenagroup.com. A replay of the webcast will be archived and available for replay for 90 days.

ABOUT AVICENA®
Avicena® Group, Inc. (OTCBB: AVGO) is a late stage biotechnology company focused on developing products based on its proprietary understanding of the regulation of cellular energy processes. The company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). The company is currently analyzing data from its Phase IIb/III trial in ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease). Near term, Avicena intends to initiate both a Phase III trial in Huntington's disease, and a Phase III trial in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary ingredients to skin care manufacturers.

Contact:
The Ruth Group (on behalf of The Avicena Group)
Sara Ephraim / John Quirk (investors)
(646) 536-7002 / 7029
sephraim@theruthgroup.com
jquirk@theruthgroup.com

Janine McCargo (media)
(646) 536-7033
jmccargo@theruthgroup.com